Protection by amifostine of cyclophosphamide-induced myelosuppression

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The dose and schedule of administration of chemotherapeutic agents are often dictated by their bone marrow toxicity. Cumulative bone marrow damage may be associated with chronic exposure to chemotherapeutic agents such as alkylating agents. Amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA), a cytoprotective agent, protects bone marrow from this type of cumulative toxicity. Three well-controlled clinical trials have shown that amifostine can ameliorate cumulative bone marrow toxicity and the acute and chronic neutropenic and/or thrombocytopenic effects of cyclophosphamide. In a pivotal phase III study of cisplatin/cyclophosphamide with or without amifostine, amifostine treatment reduced course-by-course cumulative bone marrow damage when compared with the course-by-course cumulative myelosuppression experienced by those treated with cisplatin/cyclophosphamide alone. Despite this clinically significant cytoprotection, amifostine treatment did not adversely affect pathologically proven complete response, overall objective response rates, or survival duration associated with cisplatin/cyclophosphamide chemotherapy.

Original languageEnglish (US)
Pages (from-to)37-40
Number of pages4
JournalSeminars in Oncology
Volume26
Issue number2 SUPPL. 7
StatePublished - 1999

Fingerprint

Amifostine
Cyclophosphamide
Bone Marrow
Cisplatin
Cytoprotection
Alkylating Agents
Controlled Clinical Trials
Appointments and Schedules
Drug Therapy
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Protection by amifostine of cyclophosphamide-induced myelosuppression. / Alberts, David S.

In: Seminars in Oncology, Vol. 26, No. 2 SUPPL. 7, 1999, p. 37-40.

Research output: Contribution to journalArticle

@article{5ea54895cf1a47c68ce9bd14c454e68f,
title = "Protection by amifostine of cyclophosphamide-induced myelosuppression",
abstract = "The dose and schedule of administration of chemotherapeutic agents are often dictated by their bone marrow toxicity. Cumulative bone marrow damage may be associated with chronic exposure to chemotherapeutic agents such as alkylating agents. Amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA), a cytoprotective agent, protects bone marrow from this type of cumulative toxicity. Three well-controlled clinical trials have shown that amifostine can ameliorate cumulative bone marrow toxicity and the acute and chronic neutropenic and/or thrombocytopenic effects of cyclophosphamide. In a pivotal phase III study of cisplatin/cyclophosphamide with or without amifostine, amifostine treatment reduced course-by-course cumulative bone marrow damage when compared with the course-by-course cumulative myelosuppression experienced by those treated with cisplatin/cyclophosphamide alone. Despite this clinically significant cytoprotection, amifostine treatment did not adversely affect pathologically proven complete response, overall objective response rates, or survival duration associated with cisplatin/cyclophosphamide chemotherapy.",
author = "Alberts, {David S}",
year = "1999",
language = "English (US)",
volume = "26",
pages = "37--40",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 7",

}

TY - JOUR

T1 - Protection by amifostine of cyclophosphamide-induced myelosuppression

AU - Alberts, David S

PY - 1999

Y1 - 1999

N2 - The dose and schedule of administration of chemotherapeutic agents are often dictated by their bone marrow toxicity. Cumulative bone marrow damage may be associated with chronic exposure to chemotherapeutic agents such as alkylating agents. Amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA), a cytoprotective agent, protects bone marrow from this type of cumulative toxicity. Three well-controlled clinical trials have shown that amifostine can ameliorate cumulative bone marrow toxicity and the acute and chronic neutropenic and/or thrombocytopenic effects of cyclophosphamide. In a pivotal phase III study of cisplatin/cyclophosphamide with or without amifostine, amifostine treatment reduced course-by-course cumulative bone marrow damage when compared with the course-by-course cumulative myelosuppression experienced by those treated with cisplatin/cyclophosphamide alone. Despite this clinically significant cytoprotection, amifostine treatment did not adversely affect pathologically proven complete response, overall objective response rates, or survival duration associated with cisplatin/cyclophosphamide chemotherapy.

AB - The dose and schedule of administration of chemotherapeutic agents are often dictated by their bone marrow toxicity. Cumulative bone marrow damage may be associated with chronic exposure to chemotherapeutic agents such as alkylating agents. Amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA), a cytoprotective agent, protects bone marrow from this type of cumulative toxicity. Three well-controlled clinical trials have shown that amifostine can ameliorate cumulative bone marrow toxicity and the acute and chronic neutropenic and/or thrombocytopenic effects of cyclophosphamide. In a pivotal phase III study of cisplatin/cyclophosphamide with or without amifostine, amifostine treatment reduced course-by-course cumulative bone marrow damage when compared with the course-by-course cumulative myelosuppression experienced by those treated with cisplatin/cyclophosphamide alone. Despite this clinically significant cytoprotection, amifostine treatment did not adversely affect pathologically proven complete response, overall objective response rates, or survival duration associated with cisplatin/cyclophosphamide chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0033035395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033035395&partnerID=8YFLogxK

M3 - Article

C2 - 10348259

AN - SCOPUS:0033035395

VL - 26

SP - 37

EP - 40

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 7

ER -